Brief: Amylyx Pharmaceuticals Q4 Operating Income USD -36.605 Million Versus. Ibes Estimate USD -40.4 Million
03/03/2026 12:45
March 3 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS Q4 OPERATING INCOME USD -36.605 MILLION VERSUS. IBES ESTIMATE USD -40.4 MILLION AMYLYX PHARMACEUTICALS Q4 OPERATING EXPENSES USD 36.605 MILLION AMYLYX PHARMACEUTICALS Q4 PRETAX PROFIT USD -32.953 MILLION VERSUS. IBES ESTIMATE USD -39 MILLION AMYLYX PHARMACEUTICALS Q4 CASH & INVESTMENTS USD 317 MILLION AMYLYX PHARMACEUTICALS INC - PHASE 3 LUCIDITY TRIAL TOPLINE DATA ANTICIPATED IN Q3 2026 & COMMERCIAL LAUNCH IN 2027 AMYLYX PHARMACEUTICALS INC - CASH RUNWAY EXPECTED TO FUND OPERATIONS THROUGH POTENTIAL AVEXITIDE COMMERCIALIZATION AND INTO 2028 Source text: ID:nBwbp8fZXa Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock